Video

Emerging Therapies in Prostate Cancer

For High-Definition, Click

Raoul D. Concepcion, MD, introduces the topic of emerging therapies in patients with castration-resistant prostate cancer. Currently, in the docetaxel failure state, cabazitaxel, abiraterone, and enzalutamide are approved.

Concepcion highlights several key agents in phase III clinical trials. Alpharadin or radium-223 is an alpha radiopharmaceutical that has a narrow depth of penetration but has a survival benefit alone as well as response for pain relief and reduction of skeletal-related events.

Concepcion also mentions Oteronel or TAK-700, an oral agent, and Aragon or 509, an androgen signaling inhibitor.

Related Videos
Marc Machaalani, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Razane El Hajj Chehade, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Antonio Cigliola, MD
Brian I. Rini, MD, FASCO
Sam Brondfield, MD, MA
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Karl Semaan, MD, MSc